FDA Oncology Announcements

Announcements Trials

Anti-C5 × Other × Clear all

Conditions

Drug Classes

Megakaryocyte growth factor 7 MEK inhibitor 4 BTK inhibitor 2 Erythrocyte growth factor 2 Factor IXa/Xa bridging 2 Granulocyte colony-stimulating factor 2 JAK inhibitor 2 Low molecular weight heparin 2 Anti-C5 1 Anti-CD20 1 Anti-CSF1R 1 Anti-GD2 1 Anti-P-selectin 1 Anti-PD-1 1 Anti-dabigatran antibody fragment 1 Anti-vWF 1 Antimetabolite 1 Cellular therapy 1 Chemotherapy protective agent 1 EDTA derivative 1 Factor Xa inhibitor 1 Fluoropyrimidine 1 Hemoglobin S polymerization inhibitor 1 Iron chelating agent 1 MTOR inhibitor 1 PI3K alpha inhibitor 1 Profibrinolytic 1 ROCK2 inhibitor 1 Replacement therapy 1 SYK inhibitor 1 TGF-beta inhibitor 1

1 Announcement

Eculizumab (Soliris)

Drug: Soliris (eculizumab) · Anti-C5 antibody
Condition: Classical hematology

Data powered by HemOnc (CC BY 4.0) Colophon ⚡